Stock Region Penny Picks
Good Day, Stock Region Family! 🚀
Good Day, Stock Region Family! 🚀
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer to sell any securities. Trading stocks involves significant risk, and you should always do your own due diligence or consult with a qualified financial advisor before making any investment decisions. The opinions expressed here are solely those of the author and Stock Region.
Let’s be honest—waking up to a market that’s constantly evolving is half the thrill, isn’t it? Today is one of those days where the biotech and defense sectors are screaming for attention. We’re seeing some truly fascinating shifts in how companies are tackling everything from mental health to military tech. It feels like 2026 is kicking off with some serious momentum.
Grab your coffee (or your third one, I won’t judge), and let’s dive into the watchlist.
$NRXP - NRx Pharma
The News: NRx has partnered with the neurocare Group to build a nationwide network of clinics. Their goal? Offering integrated care for depression, PTSD, and other mental health disorders.
This hits home. Mental health care is desperate for innovation, and seeing a structured, nationwide approach is refreshing. If they can execute this rollout effectively, they aren’t just looking at a revenue stream; they’re looking at becoming a household name in a critical sector. A nationwide network is ambitious, but fortune favors the bold.
$RDHL - RedHill Biopharma
The News: Two big updates here. First, their drug RHB-102 is progressing in multiple gastrointestinal (GI) indications. Second—and this is the juicy part—it’s targeting side effects related to GLP-1 therapies (think Ozempic and Mounjaro).
This is a brilliant strategic pivot. The weight loss drug market is exploding, but the side effects (nausea, vomiting) are the biggest hurdle for patients. By positioning RHB-102 as the solution to keep people on these life-changing drugs, RedHill is essentially selling shovels during a gold rush. If approved, this could be massive for titration success.
$MOBX - Mobix Labs
The News: Mobix is powering up U.S. defense operations with a veteran Defense GM taking the helm and plans for a larger, military-approved facility.
There is nothing quite as stabilizing for a stock as government contracts and defense sector integration. Bringing in a veteran GM signals they are getting serious about navigating the complexities of military procurement. Expansion plans usually mean one thing: they expect demand. This is a solid play for those watching the defense tech space.
$ALT - Altimmune
The News: The FDA just granted Breakthrough Therapy Designation for Pemvidutide in treating MASH (metabolic dysfunction-associated steatohepatitis).
“Breakthrough Therapy Designation” are the three magic words every biotech investor loves to hear. It fast-tracks development and review. MASH is a notoriously difficult condition to treat with a huge addressable market. Altimmune just got a major vote of confidence from the FDA, and that changes the risk profile significantly.
$GHRS - GH Research
The News: The FDA has lifted the clinical hold on GH001. They are now cleared to initiate a global Phase 3 trial in 2026.
Finally! Clinical holds are like purgatory for biotech stocks. The fact that the FDA lifted this and cleared the path for Phase 3 is a massive green light. It removes a huge overhang of uncertainty. Now, it’s all about execution on the global stage.
$JCSE - JE Cleantech Holdings
The News: They’ve declared a cash dividend.
In a world of high-growth speculation, sometimes it’s nice to see a company just... give money back to shareholders. Dividends signal financial health and confidence in cash flow. It’s a boring update compared to FDA breakthroughs, but “boring” pays the bills.
$MNTS - Momentus
The News: Momentus announced an additively manufactured (3D printed) fuel tank developed with Velo3D. It’s set for flight testing aboard the Vigoride-7 vehicle.
Space tech is just cool, plain and simple. Using 3D printing for fuel tanks sounds like science fiction, but it’s happening right now. This collaboration with Velo3D shows they are pushing the boundaries of manufacturing efficiency in space. If the flight test goes well, it validates their tech stack in a real-world (or out-of-world) environment.
That’s the roundup for today! Keep your eyes peeled and your charts ready. Let’s make it a great trading day.
- The Stock Region Team
Disclaimer: This newsletter is intended for educational and entertainment purposes only. The author may hold positions in the stocks mentioned. Stock market investments are subject to market risks, read all scheme-related documents carefully. Past performance is not indicative of future results. No content herein should be construed as legal or tax advice.